News | November 10, 2022
Lupin Q2 FY2023 revenue remains flat
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
The Group will continue to make proactive investments of its management resources in the life science business
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
The acquisition is for an enterprise value of Rs. 218 crores
Subscribe To Our Newsletter & Stay Updated
